Mark Croskery - 13 Dec 2024 Form 4 Insider Report for Mycotopia Therapies, Inc. (AIBT)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
17 Dec 2024, 12:27:14 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mark Croskery

Key filing fact

Mark Croskery filed Form 4 for Mycotopia Therapies, Inc. (AIBT) on 17 Dec 2024.

Key facts

  • This page summarizes Mark Croskery's Form 4 filing for Mycotopia Therapies, Inc. (AIBT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 17 Dec 2024, 12:27.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: +$140,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TPIA transaction

Common Stock

Award

Transaction value
$140,000
Shares
+10,000,000
Change %
+59130%
Price
$0.0140
Shares after
10,016,912
Date
13 Dec 2024
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares received in lieu of cash for a portion of the filer's director's fees.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .